Chronic myeloid leukemia in first chronic phase not responding to α-interferon: Outcome and prognostic factors after antologous transplantation

Bone Marrow Transplantation

Volumn 24, Issue 3, 1999, Pages 259-264

  Boiron, J M ^h   Cahn, J Y ^a   Meloni, G ^b   Carlo Stella, C ^c   Bandini, G ^d   Reman, O ^e   Milpied, N ^f   Apperley, J ^g   Reiffers, J ⁱ  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g HAMMERSMITH HOSPITAL   (United Kingdom)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ NONE

Author keywords

Autologous transplantation; CML; Interferon

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; HYDROXYUREA; MELPHALAN;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; HUMAN; HUMAN CELL; INTERSTITIAL PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032766648     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701891     Document Type: Article

References (24)

1. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87: 3069-3081.
2. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993; 82: 398-407.
3. The Italian Cooperative Study Group on Chronic Myelogenous Leukemia. Interferon-alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
4. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-261.
5. 1-negative progenitors in treated as well as newly diagnosed patients. Blood 1984; 63: 1172-1177.
6. + cell population from peripheral blood of chronic myelogenous leukemia patients contains BCR-ABL negative progenitor cells. Exp Hematol 1995; 23: 1509-1514.
7. Coulombel L, Kalousek DK, Eaves CJ et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. New Engl J Med 1983; 308: 1493-1498.
8. Reiffers J, Goldman J, Meloni G et al. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 407-410.
9. Haines ME, Goldman J, Worsley AM et al. Chemotherapy and autografting for chronic granulocytic leukemia in transformation: probable prolongation of survival for some patients. Br J Haematol 1984; 58: 711-721.
10. McGlave PB, Arthur D, Miller WJ et al. Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 1990; 6: 115-120.
11. Carlo-Stella C, Mangoni L, Almici C et al. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 1994; 14: 425-432.
12. Gewirtz AM. Oligodeoxynucleotide-based therapeutics for human leukemias. Stem Cells 1993; 11 (Suppl. 3): 96-103.
13. de Fabritiis P, Petti MC, Montefusco E et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998; 91: 3156-3162.
14. Barnett MJ, Eaves CJ, Phillips GL et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84: 724-732.
15. Carella AM, Chimirri F, Podesta M et al. High-dose chemoradiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant 1996; 17: 201-205.
16. Cony-Makhoul P, Marit G, Boiron J-M et al. Busulphan and melphalan prior to autologous transplantation for myeloid malignancies. Bone Marrow Transplant 1995; 16: 69-71.
17. Talpaz M, Kantarjian HM, McCredie KB et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon α-A in chronic myelogenous leukemia. New Engl J Med 1986; 314: 1065-1069.
18. Brito-Babapulle F, Bowcock SJ, Marcus RE et al. Autografting for patients with chronic myeloid leukemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Haematol 1989; 73: 76-81.
19. Hoyle C, Gray R, Goldman J. Autografting for patients with chronic myelogenous leukemia in chronic phase. Br J Haematol 1994; 86: 76-81.
20. Mughal T, Hoyle C, Goldman J. Autografting for patients with chronic myeloid leukemia - The Hammersmith experience. Stem Cells 1993; 11 (Suppl. 3): 20-22.
21. Talpaz M, Kantarjian H, Liang J et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 1995; 85: 3257-3263.
22. Khouri IF, Kantarjian HM, Talpaz M et al. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant 1996; 17: 775-779.
23. Sacchi S, Kantarjian HM, Smith TL et al. Early treatment decisions with interferon-alfa in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 1998; 16: 882-889.
24. Mahon FX, Fabères C, Boiron JM et al. High response rate using recombinant alpha interferon in patients with newly diagnosed chronic myeloid leukemia (CML): analysis of predictive factors. Blood 1996; 88 (Suppl. 1): 638a.